Geographic differences in temporal incidence trends of hepatitis C virus infection among people who inject drugs: The InC3 collaboration

Clinical Infectious Diseases

Volumn 64, Issue 7, 2017, Pages 860-869

  Morris, Meghan D ^a   Shiboski, Stephen ^a   Bruneau, Julie ^b   Hahn, Judith A ^a   Hellard, Margaret ^c   Prins, Maria ^d   Cox, Andrea L ^e   Dore, Gregory ^f   Grebely, Jason ^f   Kim, Arthur Y ^g   Lauer, Georg M ^g   Lloyd, Andrew ^f,h   Rice, Thomas ^a   Shoukry, Naglaa ^b   Maher, Lisa ^f   Page, Kimberly ⁱ  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c BURNET INSTITUTE   (Australia)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e DEPARTMENT OF PATHOLOGY   (United States)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h UNIVERSITY OF NEW SOUTH WALES   (Australia)

ⁱ UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Epidemiology; Harm reduction strategies; Hepatitis C virus (HCV); Incidence trends; People who inject drugs

Indexed keywords

AMPHETAMINE; BUPRENORPHINE; COCAINE; DIAMORPHINE; METHADONE; METHAMPHETAMINE;

ADULT; ARTICLE; BEHAVIOR; CALIFORNIA; CANADA; COHORT ANALYSIS; FEMALE; GEOGRAPHIC DISTRIBUTION; HEPATITIS C; HEPATITIS C VIRUS; HIGH INCOME COUNTRY; HUMAN; INCIDENCE; INFECTION RISK; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MARYLAND; MASSACHUSETTS; NEEDLE SHARING; NETHERLANDS; NONHUMAN; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; TEMPORAL ANALYSIS; TREND STUDY; CLINICAL TRIAL; DRUG USE; FOLLOW UP; GENETICS; HEALTH SURVEY; HEPACIVIRUS; MULTICENTER STUDY; RISK ASSESSMENT; SPATIOTEMPORAL ANALYSIS; STATISTICS AND NUMERICAL DATA; TRANSMISSION; VIROLOGY; YOUNG ADULT;

ADULT; COHORT STUDIES; DRUG USERS; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; INCIDENCE; LOST TO FOLLOW-UP; MALE; POPULATION SURVEILLANCE; RISK ASSESSMENT; RISK FACTORS; SPATIO-TEMPORAL ANALYSIS; YOUNG ADULT;

EID: 85018310244     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw869     Document Type: Article

References (40)

1. Aceijas C, Rhodes T. Global estimates of prevalence of HCV infection among injecting drug users. Int J Drug Policy 2007; 18:352-8.
2. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57:1333-42.
3. Patti AM, Santi AL, Pompa MG, et al. Viral hepatitis and drugs: A continuing problem. Int J Epidemiol 1993; 22:135-9.
4. Hagan H, Des Jarlais DC, Stern R, et al. HCV synthesis project: preliminary analyses of HCV prevalence in relation to age and duration of injection. Int J Drug Policy 2007; 18:341-51.
5. Sievert W, Altraif I, Razavi HA, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int 2011; 31(suppl 2):61-80.
6. Pouget ER, Hagan H, Des Jarlais DC. Meta-analysis of hepatitis C seroconversion in relation to shared syringes and drug preparation equipment. Addiction 2012; 107:1057-65.
7. Turner KM, Hutchinson S, Vickerman P, et al. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction 2011; 106:1978-88.
8. Grebely J, Morris MD, Rice TM, et al; InC Study Group. Cohort profile: The international collaboration of incident HIV and hepatitis C in injecting cohorts (InC3) study. Int J Epidemiol 2013; 42:1649-59.
9. Cox AL, Netski DM, Mosbruger T, et al. Prospective evaluation of community-acquired acute-phase hepatitis C virus infection. Clin Infect Dis 2005; 40:951-8.
10. Page K, Hahn JA, Evans J, et al. Acute hepatitis C virus infection in young adult injection drug users: A prospective study of incident infection, resolution, and reinfection. J Infect Dis 2009; 200:1216-26.
11. Bruneau J, Roy E, Arruda N, Zang G, Jutras-Aswad D. The rising prevalence of prescription opioid injection and its association with hepatitis C incidence among street-drug users. Addiction 2012; 107:1318-27.
12. Maher L, Jalaludin B, Chant KG, et al. Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. Addiction 2006; 101:1499-508.
13. White B, Dore GJ, Lloyd AR, Rawlinson WD, Maher L. Opioid substitution therapy protects against hepatitis C virus acquisition in people who inject drugs: The HITS-c study. Med J Aust 2014; 201:326-9.
14. van den Berg CH, Smit C, Bakker M, et al. Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users. Eur J Epidemiol 2007; 22:183-93.
15. Sacks-Davis R, Daraganova G, Aitken C, et al. Hepatitis C virus phylogenetic clustering is associated with the social-injecting network in a cohort of people who inject drugs. PLoS One 2012; 7:e47335.
16. Page-Shafer K, Pappalardo BL, Tobler LH, et al. Testing strategy to identify cases of acute hepatitis C virus (HCV) infection and to project HCV incidence rates. J Clin Microbiol 2008; 46:499-506.
17. Buning EC. Effects of Amsterdam needle and syringe exchange. Int J Addict 1991; 26:1303-11.
18. Witteveen E, Schippers G. Needle and syringe exchange programs in Amsterdam. Subst Use Misuse 2006; 41(6-7):835-6.
19. Razali K, Thein HH, Bell J, et al. Modelling the hepatitis C virus epidemic in Australia. Drug Alcohol Depend 2007; 91(2-3):228-35.
20. Schechter MT, Strathdee SA, Cornelisse PG, et al. Do needle exchange programmes increase the spread of HIV among injection drug users? An investigation of the Vancouver outbreak. AIDS 1999; 13:F45-51.
21. Hahn JA, Page-Shafer K, Lum PJ, Ochoa K, Moss AR. Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco. Hepatology 2001; 34:180-7.
22. Hahn JA, Vranizan KM, Moss AR. Who uses needle exchange? A study of injection drug users in treatment in San Francisco, 1989-1990. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 15: 157-64.
23. Bruneau J, Lamothe F, Franco E, et al. High rates of HIV infection among injection drug users participating in needle exchange programs in Montreal: results of a cohort study. Am J Epidemiol 1997; 146:994-1002.
24. Patrick DM, Tyndall MW, Cornelisse PG, et al. Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection. CMAJ 2001; 165:889-95.
25. Miller CL, Tyndall M, Spittal P, Li K, Palepu A, Schechter MT. Risk-taking behaviors among injecting drug users who obtain syringes from pharmacies, fixed sites, and mobile van needle exchanges. J Urban Health 2002; 79:257-65.
26. Strathdee SA, Patrick DM, Currie SL, et al. Needle exchange is not enough: lessons from the Vancouver injecting drug use study. AIDS 1997; 11: F59-65.
27. Hagan H, McGough JP, Thiede H, Weiss NS, Hopkins S, Alexander ER. Syringe exchange and risk of infection with hepatitis B and C viruses. Am J Epidemiol 1999; 149:203-13.
28. Tsui JI, Evans JL, Lum PJ, Hahn JA, Page K. Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users. JAMA Intern Med 2014; 174:1974-81.
29. Nolan S, Dias Lima V, Fairbairn N, et al. The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users. Addiction 2014; 109:2053-9.
30. Substance Abuse and Mental Health Services Administration. Federal guidelines for opioid treatment programs. Rockville, MD: SAMHSA, 2015.
31. Van Den Berg C, Smit C, Van Brussel G, Coutinho R, Prins M; Amsterdam Cohort. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction 2007; 102:1454-62.
32. Hagan H, Pouget ER, Des Jarlais DC. A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. J Infect Dis 2011; 204:74-83.
33. Martin NK, Hickman M, Hutchinson SJ, Goldberg DJ, Vickerman P. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis 2013; 57(suppl 2):S39-45.
34. Platt L, Reed J, Minozzi S, et al. Effectiveness of needle/syringe programmes and opiate substitution therapy in preventing HCV transmission among people who inject drugs. Cochrane Database Syst Rev 2016; 2016.
35. Rice E, Milburn NG, Rotheram-Borus MJ, Mallett S, Rosenthal D. The effects of peer group network properties on drug use among homeless youth. Am Behav Sci 2005; 48:1102-23.
36. De P, Jolly A, Cox J, Boivin JF. Characterizing the drug-injecting networks of cocaine and heroin injectors in Montreal. Can J Public Health 2006; 97:207-9.
37. 114th Congress of the United States. Consolidated Appropriations Act, 2016. Available at: https://www.congress.gov/bill/114th-congress/house-bill/2029/text. Accessed 3 January 2017.
38. Kohli A, Shaffer A, Sherman A, Kottilil S. Treatment of hepatitis C: A systematic review. JAMA 2014; 312:631-40.
39. Martin NK, Vickerman P, Grebely J, et al. Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals. Hepatology 2013; 58:1598-609.
40. Smith DJ, Combellick J, Jordan AE, Hagan H. Hepatitis C virus (HCV) disease progression in people who inject drugs (PWID): A systematic review and meta-analysis. Int J Drug Policy 2015; 26:911-21.